Ayhan Ali, Taskiran Cagatay, Bozdag Gurkan, Altinbas Sibel, Altinbas Akif, Yuce Kunter
Hacettepe University, Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Kadin Hastaliklari ve Doğum A.D., Hamamönü-Ankara, Turkey.
Eur J Obstet Gynecol Reprod Biol. 2005 Dec 1;123(2):230-4. doi: 10.1016/j.ejogrb.2005.04.021. Epub 2005 Jul 18.
The purpose of this study was to evaluate the treatment regimens used for patients with endodermal sinus tumors (EST), and also to examine the prognostic value of surgicopathological variables.
Twenty-two patients treated for pure EST, and seven patients who had mixed germ cell tumors with EST components were included. Initial surgery consisting of surgical staging to achieve optimal debulking was the principal mode of therapy. Data were obtained from patients' files, a special gynecologic oncology database, and pathology records.
The median age at the time of diagnosis was 18 (range 8-45). Sixteen patients had stage I (55%), and 13 (45%) had stage II-IV disease. As an adjuvant therapy 18 patients (62%) received platin-based chemotherapy, three patients (10%) had non-platin-based chemotherapy, four patients (14%) had radiotherapy, and four patients (14%) had combined radiotherapy plus non-platin-based chemotherapy. The 5-year disease-free and overall survival rates were 47 and 48%, respectively. Survival rates were dismal in patients with stage II-IV disease (P < 0.001). Platin-based chemotherapy achieved significant survival benefit (P = 0.03 and P < 0.001, respectively). Fertility-saving surgery had an overall survival no worse than those who underwent more extensive surgery. There was no significant survival difference with respect to age, histology, and tumor size.
Fertility-sparing surgery with a postoperative platin-based combination chemotherapy should be the selected mode of treatment.
本研究旨在评估用于治疗内胚窦瘤(EST)患者的治疗方案,并探讨外科病理变量的预后价值。
纳入22例接受单纯EST治疗的患者,以及7例患有混合性生殖细胞肿瘤且包含EST成分的患者。以手术分期以实现最佳肿瘤减灭的初始手术是主要治疗方式。数据来自患者病历、一个特殊的妇科肿瘤数据库和病理记录。
诊断时的中位年龄为18岁(范围8 - 45岁)。16例患者为I期(55%),13例(45%)为II - IV期疾病。作为辅助治疗,18例患者(62%)接受了铂类化疗,3例患者(10%)接受了非铂类化疗,4例患者(14%)接受了放疗,4例患者(14%)接受了放疗加非铂类化疗联合治疗。5年无病生存率和总生存率分别为47%和48%。II - IV期疾病患者的生存率较差(P < 0.001)。铂类化疗取得了显著的生存获益(分别为P = 0.03和P < 0.001)。保留生育功能手术的总生存率不低于接受更广泛手术的患者。在年龄、组织学和肿瘤大小方面,生存无显著差异。
保留生育功能手术加术后铂类联合化疗应作为首选治疗方式。